Publications
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Faculty of Pharmacy in Hradec Králové
- Trans-epidermal absorption of polycyclic aromatic hydrocarbons2018 | Faculty of Medicine in Hradec Králové
Loading network view...